Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 8/20 | 0.40 |
| ▸ | GBA1 | P04062 | 6/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917902 | 0.91 | GNAI3 (0.50) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL17718458 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1044920 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL4921737 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL9155873 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL24210534 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL31020849 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL20746945 | 0.78 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL23139613 | 0.77 | GNAI3 (0.50) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL530708 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | GNAI3 304/4885GNAO1 387/4885GNAI1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.